Evidence map›Paper›PMID 30550594›Full record

ArticlePLoS neglected tropical diseases2018

Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test.

Oliver Bärenbold, Amadou Garba, Daniel G Colley, Fiona M Fleming, Ayat A Haggag, Reda M R Ramzy, Rufin K Assaré, Edridah M Tukahebwa, Jean B Mbonigaba, Victor Bucumi and 9 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. How Does Treatment Coverage and Proportion Never Treated Influence the Success of Schistosoma mansoni Elimination as a Public Health Problem by 2030?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Detecting twoFrontiers in parasitology · 2024
    Article
  16. Article
  17. Article
  18. Reproducibility matters: intra- and inter-sample variation of the point-of-care circulating cathodic antigen test in twoPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Oliver BärenboldSwiss Tropical and Public Health Institute, Basel, Switzerland.
Amadou GarbaDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Daniel G ColleyCenter for Tropical and Emerging Global Diseases and Department of Microbiology, University of Georgia, Athens, GA, United States of America.ORCID 0000-0002-9381-8420
Fiona M FlemingSchistosomiasis Control Initiative, Imperial College, London, United Kingdom.
Ayat A HaggagMinistry of Health and Population, Cairo, Egypt.
Reda M R RamzyNational Nutrition Institute, General Organisation for Teaching Hospitals and Institutes, Cairo, Egypt.
Rufin K AssaréSwiss Tropical and Public Health Institute, Basel, Switzerland.
Edridah M TukahebwaVector Control Division, Ministry of Health, Kampala, Uganda.
Jean B MbonigabaMinistry of Health, Kigali, Rwanda.
Victor BucumiProgramme National Intégré de Lutte contre les Maladies Tropicales Négligées et la Cécité au Burundi, Bujumbura, Burundi.
Biruck KebedeMinistry of Health, Addis Ababa, Ethiopia.
Makoy S YibiNeglected Tropical Disease Department, Ministry of Health, Juba, South Sudan.
Aboulaye MeitéProgramme National de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive, Ministère de la Santé et de l'Hygiène Publique, Abidjan, Côte d'Ivoire.
Jean T CoulibalySwiss Tropical and Public Health Institute, Basel, Switzerland.
Eliézer K N'GoranCentre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Louis-Albert Tchuem TchuentéLaboratory of Parasitology and Ecology, University of Yaoundé I, Yaoundé, Cameroon.
Pauline MwinziCentre for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.
Jürg UtzingerSwiss Tropical and Public Health Institute, Basel, Switzerland.
Penelope VounatsouSwiss Tropical and Public Health Institute, Basel, Switzerland.ORCID 0000-0002-4904-5352

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundIntervention guidelines against Schistosoma mansoni are based on the Kato-Katz technique. However, Kato-Katz thick smears show low sensitivity, especially for light-intensity infections. The point-of-care circulating cathodic antigen (POC-CCA) is a promising rapid diagnostic test detecting antigen output of living worms in urine and results are reported as trace, 1+, 2+, and 3+. The use of POC-CCA for schistosomiasis mapping, control, and surveillance requires translation of the Kato-Katz prevalence thresholds into POC-CCA relative treatment cut-offs. Furthermore, the infection status of egg-negative but antigen-positive individuals and the intensity-dependent sensitivity of POC-CCA should be estimated to determine its suitability for verification of disease elimination efforts. METHODOLOGY: We used data from settings in Africa and the Americas characterized by a wide range of S. mansoni endemicity. We estimated infection intensity-dependent sensitivity and specificity of each test at the unit of the individual, using a hierarchical Bayesian egg-count model that removes the need to define a 'gold' standard applied to data with multiple Kato-Katz thick smears and POC-CCA urine cassette tests. A simulation study was carried out based on the model estimates to assess the relation of the two diagnostic tests for different endemicity scenarios. PRINCIPAL

findingsPOC-CCA showed high specificity (> 95%), and high sensitivity (> 95%) for moderate and heavy infection intensities, and moderate sensitivity (> 75%) for light infection intensities, and even for egg-negative but antigen-positive infections. A 10% duplicate slide Kato-Katz thick smear prevalence corresponded to a 15-40% prevalence of ≥ trace-positive POC-CCA, and 10-20% prevalence of ≥ 1+ POC-CCA. The prevalence of ≥ 2+ POC-CCA corresponded directly to single slide Kato-Katz prevalence for all prevalence levels. CONCLUSIONS/SIGNIFICANCE: The moderate sensitivity of POC-CCA, even for very light S. mansoni infections where the sensitivity of Kato-Katz is very low, and the identified relationship between Kato-Katz and POC-CCA prevalence thresholds render the latter diagnostic tool useful for surveillance and initial estimation of elimination of S. mansoni. For prevalence below 10% based on a duplicate slide Kato-Katz thick smear, we suggest using POC-CCA including trace results to evaluate treatment needs and propose new intervention thresholds that need to be validated in different settings.

Indexed as

Models, StatisticalPoint-of-Care SystemsAfricaAmericasAnimalsChemopreventionDiagnostic Tests, RoutineFecesFemaleHumansParasite Egg CountPrevalenceSchistosoma mansoniSchistosomiasis mansoniSensitivity and Specificity

Identifiers

PMID30550594
PMCPMC6310297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.